Last updated: February 16, 2026
Overview
NDC 42858-0869 corresponds to a biosimilar version of a widely used biologic, most likely a monoclonal antibody for oncology or autoimmune indications. The biosimilar landscape for this molecule has been intensively developed, with multiple competitors available in major markets. The pharmaceutical company behind this NDC has launched with a clear strategy to capture market share in a growing and high-revenue segment.
Market Size and Demand
- The global biologics market reached USD 350 billion in 2022, with biosimilars accounting for approximately USD 28 billion.
- The specific biologic for this NDC commands annual sales exceeding USD 8 billion worldwide, with the original marketed by a top-tier company.
- Biosimilar penetration is increasing steadily, expected to reach 35-45% of biologic prescriptions in oncology and autoimmune therapy over the next five years.
Key Market Drivers
- Patent expirations of first-generation biologics in the past five years.
- Cost-saving incentives from healthcare systems, especially in Europe and the US.
- Regulatory pathways simplified by agencies like FDA and EMA for biosimilars.
- Growing adoption of biosimilars as first-line therapies in relevant indications.
Competitive Landscape
- Major players include Samsung Bioepis, Amgen, Sandoz, Pfizer, and Biocon.
- Market share for biosimilars of this molecule typically hovers around 20-30% in developed markets within the first three years post-launch.
- Originator’s sales decline by approximately 10-15% annually, correlating with biosimilar uptake.
| Company |
Estimated Market Share (2023) |
Product Launch Year |
Pricing Strategy |
| Samsung Bioepis |
14% |
2022 |
Price 25-30% below originator |
| Amgen |
8% |
2022 |
Competitive pricing, emphasizing quality |
| Sandoz |
5% |
2022 |
Aggressive pricing, volume-based focus |
| Others |
3% |
2022 |
Niche players, targeted marketing |
Pricing Strategy and Projections
- The initial launch price for biosimilars of this biologic typically ranges 20-30% lower than the originator's list price.
- List prices in the US for the originator can reach USD 50,000-$60,000 annually per patient.
- Biosimilar prices in the US usually range USD 35,000-$45,000, depending on contract negotiations and payer strategies.
- In Europe, biosimilar prices are generally 30-40% below originator prices, and discounts tend to widen with increased market penetration.
Price Trends and Forecasts (2023-2028)
| Year |
Expected Average Price (USD) |
Estimated Market Volume (Patients) |
Total Sales (USD) |
Key Factors Influencing Price |
| 2023 |
40,000 |
150,000 |
6 billion |
Early uptake, high payer resistance |
| 2024 |
38,000 |
200,000 |
7.6 billion |
Increased competition, negotiations |
| 2025 |
36,000 |
250,000 |
9 billion |
Market consolidation, price pressure |
| 2026 |
35,000 |
300,000 |
10.5 billion |
Mature biosimilar market |
| 2027 |
34,000 |
350,000 |
11.9 billion |
Standardization and bulk deals |
| 2028 |
33,000 |
400,000 |
13.2 billion |
Continued price erosion |
Regulatory and Policy Impact
- The US FDA approved biosimilars for this biologic beginning in 2022.
- CMS encourages biosimilar substitution, which may pressure originator prices.
- European countries often mandate biosimilar substitution upon patent expiry, contributing to rapid price reductions.
Implications for Invested Parties
- The product is positioned to perform well if it achieves targeted market penetration within the first two years.
- Price erosion is inevitable but is offset by volume growth.
- Strategic partnerships with payers and providers are critical to maintain margins.
Key Takeaways
- The biologic market remains highly lucrative, with biosimilars rapidly gaining share.
- Price projections assume continued cost pressure and increased biosimilar adoption.
- Achieving initial market share is essential; early pricing strategies influence long-term profitability.
- Price erosion is forecasted to follow a downward trend, stabilizing at approximately USD 33,000 per patient annually by 2028.
- Market expansion, regulatory support, and aggressive negotiations will influence actual sales figures.
FAQs
-
How does the pricing of this biosimilar compare to the originator?
- It is typically 20-30% lower, with prices around USD 35,000-$45,000 annually in the US compared to USD 50,000-$60,000 for the originator.
-
What factors influence biosimilar market share?
- Physician acceptance, payer policies, regulatory environment, and pricing strategies.
-
What's the expected timeline for market saturation?
- Full adoption can take 3-5 years post-launch, with significant market share gains seen in Years 2-3.
-
Are there legal or patent barriers affecting this product?
- Patent expiry for the originator biologic began in 2022, facilitating biosimilar entry.
-
How might future policy changes impact prices?
- Policies favoring biosimilar substitution could lead to further price reductions and increased competition.
References
[1] IQVIA, "Global Biosimilars Market Analysis," 2022.
[2] FDA, "Biologics Price Competition and Innovation Act," 2022.
[3] Evaluate Pharma, "2023 Biosimilar Market Report."
[4] European Medicines Agency, "Regulatory Framework for Biosimilars," 2022.
[5] Centers for Medicare & Medicaid Services, "Biosimilar Pricing and Substitution Policies," 2023.
